Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Lymphoid 1Endocrine 1CNS 1

Conditions

Neuroblastoma 3Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Glioma 2Glioblastoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neoplasms 1Multiple Myeloma 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Temozolomide 19Bevacizumab 14Irinotecan 12Carboplatin 10Cyclophosphamide 9Radiosurgery 8Lomustine 8Radiotherapy 7pembrolizumab 6Vincristine 6Topotecan 6Drug Therapy 6Surgical Procedures, Operative 5Etoposide 5Doxorubicin 5Cisplatin 53-Iodobenzylguanidine 5trametinib 4Metformin 4Gemcitabine 4Dexamethasone 4Blood Specimen Collection 4poly ICLC 3dabrafenib 3Vorinostat 3Trastuzumab 3Therapeutics 3Radiation 3Paclitaxel 3Observation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Crizotinib × CNS × Clear all
NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Pfizer

Phase 1 Terminated
44 enrolled 22 charts 1 FDA
CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡